A biomarker-based platform for early diagnosis of chronic liver disease to enable personalized therapy
The Project
LIVERAIM is an exciting new IHI funded project that is working to improve early detection of chronic liver disease through the development of a new biomarker-based personalized risk calculator.
Look at the Video from ELPA
The Problem
Chronic liver diseases are a leading cause of premature deaths in Europe, presenting a significant public health concern. Liver diseases are often asymptomatic in early phase. As a result, they are frequently diagnosed at a late stage, when end-stage liver disease, also known as cirrhosis, is established and treatments are less effective. There is an urgent need to shift towards early detection and treatment of chronic liver diseases.
The Solution
The LIVERAIM project aims to create and validate a biomarker-based screening platform to enable early detection of liver disease in asymptomatic individuals, allowing for personalized and effective therapeutic interventions to halt or reverse disease progression.
We bring together the top academic researchers in the field of liver disease, Industry partners from both the biomarker and pharmaceutical industries, patient associations, leading health economists, public health experts and AI tool creators to form the LIVERAIM Consortium.
Clinical Study
Furthering the research performed in previous European Commission funded projects, the LIVERAIM Consortium will test the accuracy of existing biomarkers in identifying chronic liver diseases. The results will be analyzed using Artificial Intelligence (AI) to develop a digital biomarker screening platform. The validation of the digital platform will be performed in a large clinical study including 100.000 subjects.
Join the LiverAim projectBe part of the Clinical Study
Clinical Study
Furthering the research performed in previous European Commission funded projects, the LIVERAIM Consortium will test the accuracy of existing biomarkers in identifying chronic liver diseases. The results will be analyzed using Artificial Intelligence (AI) to develop a digital biomarker screening platform. The validation of the digital platform will be performed in a large clinical study including 100.000 subjects.
